Trial Profile
A Phase 3, Randomized, Multicenter, Single-blind, Controlled Study Evaluating Arteriovenous Fistula Outcomes With and Without a Perivascular Sirolimus-Eluting Collagen Implant
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Nov 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Arteriovenous fistula
- Focus Therapeutic Use
- Acronyms ACCESS; ACCESS I
- Sponsors Vascular Therapies
- 04 Nov 2021 Primary endpoint (Fistula Suitability for Dialysis at 6 Months (FSD6)) has not been met as per results published in the a Vascular Therapies Media Release
- 04 Nov 2021 According to Vascular Therapies Media Release. clinical results from this Phase 3 clinical trial (ACCESS 1) presented during the Late Breaking Clinical Trials section of the American Association of Nephrology Annual Meeting.
- 04 Nov 2021 Results published in the a Vascular Therapies Media Release